| Carcinoma breast stage IV
Verzenio vs Ixempra
Side-by-side clinical, coverage, and cost comparison for carcinoma breast stage iv.Deep comparison between: Verzenio vs Ixempra with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsIxempra has a higher rate of injection site reactions vs Verzenio based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Ixempra but not Verzenio, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Verzenio
Ixempra
At A Glance
Oral
Twice daily
CDK4/6 inhibitor
IV infusion
Every 3 weeks
Microtubule inhibitor (epothilone analog)
Indications
- Malignant neoplasm of breast
- Carcinoma breast stage IV
- Carcinoma breast stage IV
- Locally advanced breast cancer
Dosing
Malignant neoplasm of breast 150 mg orally twice daily in combination with tamoxifen or an aromatase inhibitor for 2 years as adjuvant treatment (or until disease recurrence or unacceptable toxicity).
Carcinoma breast stage IV 150 mg orally twice daily in combination with an aromatase inhibitor (initial therapy) or fulvestrant (after endocrine therapy progression); 200 mg orally twice daily as monotherapy (after endocrine therapy and prior chemotherapy); continue until disease progression or unacceptable toxicity.
Carcinoma breast stage IV, Locally advanced breast cancer (with capecitabine) 40 mg/m2 IV over 3 hours every 3 weeks; capecitabine 1000 mg/m2 twice daily for 2 weeks per cycle.
Carcinoma breast stage IV, Locally advanced breast cancer (single agent) 40 mg/m2 IV over 3 hours every 3 weeks.
Contraindications
—
- Neutrophil count <1500 cells/mm3 or platelet count <100,000 cells/mm3
- History of severe hypersensitivity to agents containing Cremophor EL or its derivatives (e.g., polyoxyethylated castor oil)
- Combination with capecitabine in patients with AST or ALT >2.5 x ULN or bilirubin >1 x ULN
Adverse Reactions
Most common (>=20%) diarrhea, neutropenia, nausea, abdominal pain, infections, fatigue, anemia, leukopenia, decreased appetite, vomiting, headache, alopecia, thrombocytopenia
Serious neutropenia, diarrhea, interstitial lung disease/pneumonitis, hepatotoxicity, venous thromboembolism
Postmarketing interstitial lung disease/pneumonitis
Most common (>=20%) Peripheral sensory neuropathy, fatigue/asthenia, myalgia/arthralgia, alopecia, nausea, vomiting, stomatitis/mucositis, diarrhea, musculoskeletal pain; in combination therapy also: palmar-plantar erythrodysesthesia, anorexia, abdominal pain, nail disorder, constipation.
Most common hematologic (>40%) Neutropenia, leukopenia, anemia, thrombocytopenia.
Serious Peripheral neuropathy, myelosuppression, hypersensitivity reactions, cardiac adverse reactions (myocardial infarction, arrhythmia, left ventricular dysfunction), sepsis, pneumonia, respiratory failure, acute hepatic failure.
Postmarketing Radiation recall.
Pharmacology
Abemaciclib is an inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6); in ER-positive breast cancer cells, it blocks Rb phosphorylation and cell cycle progression from G1 into S phase, resulting in senescence and apoptosis.
Ixabepilone is a semi-synthetic analog of epothilone B that binds directly to beta-tubulin subunits on microtubules, suppressing microtubule dynamic instability and blocking cells in the mitotic phase of the cell division cycle, leading to cell death.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Verzenio
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (11/12)
Ixempra
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Verzenio
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (0/8) · Qty limit (7/8)
Ixempra
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Verzenio
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Ixempra
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Breast Cancer
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: Breast Cancer
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
VerzenioView full Verzenio profile
IxempraView full Ixempra profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.